References
- Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004;83:6-15. https://doi.org/10.1016/j.ymgme.2004.08.015
- Zimran A. How I treat Gaucher disease. Blood 2011;118:1463-71. https://doi.org/10.1182/blood-2011-04-308890
- Cabrera-Salazar MA, O'Rourke E, Henderson N, Wessel H, Barranger JA. Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 2004;344:101-7. https://doi.org/10.1016/j.cccn.2004.02.018
- Lee JY, Lee BH, Kim GH, Jung CW, Lee J, Choi JH, et al. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean J Pediatr 2012;55:48-53. https://doi.org/10.3345/kjp.2012.55.2.48
- Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, et al. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;345:1479-80. https://doi.org/10.1016/S0140-6736(95)91038-7
-
Choi JH, Lee BH, Ko JM, Sohn YB, Lee JS, Kim GH, et al. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of
$Abcertin^{(R)}$ in patients with type 1 Gaucher disease. J Korean Med Sci 2015;30:378-84. https://doi.org/10.3346/jkms.2015.30.4.378 - Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010;115:4651-6. https://doi.org/10.1182/blood-2010-02-268649
- Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118:5767-73. https://doi.org/10.1182/blood-2011-07-366955
- Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9. https://doi.org/10.1016/S0002-9343(02)01150-6
- Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5. https://doi.org/10.1016/S0140-6736(00)02161-9
- Heitner R, Elstein D, Aerts J, Weely Sv, Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002;28:127-33. https://doi.org/10.1006/bcmd.2002.0497
- Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2013;36:543-53. https://doi.org/10.1007/s10545-012-9528-4
- Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009;3:407-17.
-
Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(
$^{(R)}$ ) )-treated patients. Pharmacoepidemiol Drug Saf 2015;24:329-33. https://doi.org/10.1002/pds.3760 - Cox-Brinkman J, van Breemen MJ, van Maldegem BT, Bour L, Donker WE, Hollak CE, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis 2008;31:745-52. https://doi.org/10.1007/s10545-008-0873-2
- Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, et al. Randomized, controlled trial of miglustat in Gaucher's disease type 3. Ann Neurol 2008;64:514-22. https://doi.org/10.1002/ana.21491
- Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, et al. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis 2013;51:116-24. https://doi.org/10.1016/j.bcmd.2013.04.005
- Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004;5:777-82. https://doi.org/10.1038/sj.embor.7400208
- McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, Hutto E, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 2007;91:259-67. https://doi.org/10.1016/j.ymgme.2007.04.001
- Lukina E, Watman N, Dragosky M, Pastores GM, Arreguin EA, Rosenbaum H, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 2014;53:274-6. https://doi.org/10.1016/j.bcmd.2014.04.002
- Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA 2015;313:695-706. https://doi.org/10.1001/jama.2015.459
- Peterschmitt MJ, Burke A, Blankstein L, Smith SE, Puga AC, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol 2011;51:695-705. https://doi.org/10.1177/0091270010372387
- Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 2011;46:11-4. https://doi.org/10.1016/j.bcmd.2010.07.010